Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results

2020 Year in Review - Breast Cancer - Breast Cancer

Across the MONALEESA-2, -3, and -7 clinical trials, first-line treatment with endocrine therapy and ribociclib mitigated negative effects on quality of life, global health scores, pain, and emotional functioning.

Peter A. Fasching, MD, Head, Clinical Trial Unit, and Coordinator, Breast Cancer Center and Gynecologic Oncology Center, University Hospital Erlangen, Germany, provided his expert insight on a pooled analysis of the MONALEESA-2, -3, and -7 clinical trials. These trials included patient-reported quality of life (QOL) that was in conjunction with the efficacy and safety of ribociclib combined with various endocrine therapeutic options as first- or second-line therapy for hormone receptor–positive, HER2-negative advanced breast cancer. This pooled data analysis of the MONALEESA trials provided a more robust analysis of the impact of treatment on QOL based on both pre- and postmenopausal patients receiving various endocrine therapy combinations.

A total of 1528 patients from the MONALEESA trials were assessed in this study, in which the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 was used to evaluate health-related QOL and pain. QOL was also assessed for all patients in MONALEESA-2, in patients receiving endocrine therapy as initial treatment in MONALEESA-3, and in patients receiving ribociclib or placebo plus a nonsteroidal aromatase inhibitor as endocrine therapy in MONALEESA-7. 

When treated with ribociclib, time to definitive deterioration ≥10% for global health status, pain, and emotional functioning were extended. The pooled analysis showed that median time to definitive deterioration ≥10% for global health status was 39.6 months for the group treated with ribociclib versus 33.1 months for the group administered placebo (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.66-0.94). However, median time to definitive deterioration ≥10% for pain was not reached for either the ribociclib or placebo cohorts (HR, 0.77; 95% CI, 0.61-0.97).

The median time to definitive deterioration ≥10% for emotional functioning was 46.9 months for the group treated with ribociclib and compared with 35.9 months in the group administered placebo (HR, 0.71; 95% CI, 0.59-0.85).

While the HRs for time to definitive deterioration ≥10% for social and physical functioning and fatigue favored ribociclib, the investigators noted there were wide CIs.

Global health status and QOL were maintained from baseline throughout treatment in both arms; however, at the end of treatment, it diminished. Similarly, pain management was improved from baseline and maintained during treatment but worsened at end of treatment.

Patients receiving first-line endocrine therapy plus ribociclib delayed worsening of QOL. In addition, ribociclib treatment positively affected time to definite deterioration for global health status, emotional function scores, and pain in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Source: Fasching PA, Bardia A, Nusch A, et al. Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC). Ann Oncol. 2020;31(4_suppl). Abstract 2760.

Related Items
Medicaid Expansion Significantly Improves Breast Reconstruction Disparities
William Ackerman
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Patricia Stewart
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
Cryoablation Appears Safe and Effective in Low-Risk, Early-Stage Breast Cancer
William Ackerman
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in Breast Cancer
Pembrolizumab plus Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Abemaciclib plus Endocrine Therapy Offers Invasive Disease–Free Survival Benefit in Patients with High-Risk, HR-Positive, Early-Stage Breast Cancer
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Last modified: July 22, 2021